NCT01199874已完成4 期
The Immunogenicity of Rotavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding Around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine
PATH1 个研究点 分布在 1 个国家目标入组 1,140 人开始时间: 2011年4月最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,140
- 试验地点
- 1
- 主要终点
- Seropositivity as anti-rotavirus IgA concentration >/= 20 U/ml
研究概览
简要总结
Rotavirus is one of the most common causes of severe diarrhea, responsible for 40% of all diarrhea related deaths in children worldwide. Two vaccines against Rotavirus, Rotarix® and Rotateq® were licensed in many high and middle income countries in 2006, but lack of efficacy data in low income countries had prevented WHO from making a universal recommendation of their use until recently. This study will be conducted in Pakistan and will look at two objectives:
- To compare the immunogenicity of Rotarix® vaccine when administered at 6 and 10 weeks of life and at 6, 10 and 14 weeks of life.
- To compare the immunogenicity of Rotarix® vaccine in infants breast fed at the time of vaccine administration with infants whose breast feeding is withheld for one hour before and after vaccine administration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 6 Weeks 至 18 Weeks(Child)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •6 weeks 0 days to 6 weeks 6 days age at the time of enrollment.
- •Healthy infant free of chronic or serious medical condition as determined by history and physical exam at time of enrollment into in the study.
- •Written informed consent obtained from the parents or guardians.
排除标准
- •Hypersensitivity to any of the vaccine components.
- •Use of any investigational drug or vaccine other than the study vaccine within 30 days of first dose of study vaccine or during the study.
- •Use of any immunosuppressive drugs.
- •Previous intussusception or abdominal surgery.
- •Enrolment in any other trial (Simplified Antibiotic Therapy for Neonatal Sepsis Trial, Management of Omphalitis Trial).
- •Birth weight less than 1500 grams; or if birth weight is unknown, weight less than 2000 grams on or before 28 days.
- •Immunoglobulin and/or blood products use since birth or during the study period.
结局指标
主要结局
Seropositivity as anti-rotavirus IgA concentration >/= 20 U/ml
时间窗: 6, 10, 14 and 18 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected MothersHIV InfectionRotavirus InfectionNCT00880698National Institute of Allergy and Infectious Diseases (NIAID)202
已完成
3 期
Improving Rotavirus Vaccine Immune ResponseHealthy InfantsMothersNCT01825109International Centre for Diarrhoeal Disease Research, Bangladesh300
已完成
4 期
The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and ImmunogenicityVaccine Response ImpairedVaccine Virus SheddingRotavirus InfectionNCT02992197University of Vermont220
已完成
3 期
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in IndiaInfections, RotavirusNCT00289172GlaxoSmithKline360
已完成
4 期
Safety and Immunogenicity of Sequential Rotavirus Vaccine SchedulesRotavirus InfectionNCT01266850National Institute of Allergy and Infectious Diseases (NIAID)1,384
